The secondary effects of the antihistamine chlorpheniramine on the central nervous system;Efectos secundarios del antihistamínico clorfeniramina sobre el sistema nervioso central

Revista de Neurologia

Volumn 34, Issue 12, 2002, Pages 1178-1182

  Serra Grabulosa, Josep M ^a   Sanchez Turet M ^a   Grau, C ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antihistamines; Attention; Chlorpheniramine; Human auditory system; MMN; P300; PN; Potential of disparity

Indexed keywords

ANTIHISTAMINIC AGENT; CHLORPHENIRAMINE; TERFENADINE; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST;

ALLERGIC RHINITIS; AMPLITUDE MODULATION; ATTENTION; AUDITORY SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; DROWSINESS; DRUG EFFECT; EVOKED RESPONSE; HUMAN; REVIEW; TASK PERFORMANCE; VISUOMOTOR COORDINATION; AWARENESS; CENTRAL NERVOUS SYSTEM; EVENT RELATED POTENTIAL; HEARING; METABOLISM;

ATTENTION; AUDITORY PERCEPTION; AWARENESS; CENTRAL NERVOUS SYSTEM; CHLORPHENIRAMINE; EVENT-RELATED POTENTIALS, P300; HISTAMINE; HISTAMINE H1 ANTAGONISTS; HUMANS;

EID: 0037118442     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3412.2001506     Document Type: Review

References (84)

1. 1-receptor antagonists. Comparative tolerability and safety. Drug Safety 1994; 10: 350-80.
2. Schwartz JH. Chemical messengers: small molecules and peptides. In Kandel ER, Schwartz JH, Jessell TM, eds. Principles of Neural Science. Amsterdam: Elsevier Science Publishing; 1991. p. 213-24.
3. Cooper DG, Young RC, Durant GJ, Ganellin CR. Histamine receptors. In Hansch C, Sammes PG, Taylor JB, eds. Comprehensive medicinal chemistry. The rational design, mechanistic study and therapeutic application of chemical compounds. Membranes & Receptors. Oxford: Pergamon Press; 1990. p. 323-421.
4. Oehling A. Mediadores y células que participan en las reacciones por hipersensibilidad inmediata. In Oehling A, ed. Alergología e inmunología clínica. Madrid: McGraw-Hill-Interamericana de España; 1995. p. 93-110.
5. Church MK, Bradding P, Walls AF, Okayama Y. Human mast cells and basophils. In Key AB, ed. Allergy and allergic diseases. Oxford: Blackwell Science; 1997. p. 149-70.
6. Schwartz JC, Garbarg M, Pollard H. Handbook of Physiology, the Nervous System. In Bloom FE, Mountcastle WB, Geiger SR, eds. Vol. IV: Intrinsic regulatory systems of the brain. Bethesda: American Physiological Society; 1986. p. 257-316.
7. Happola O, Soinila S, Paivarinta H, Panula P, Eranko O. Histamine-immunoreactive cells in the superior cervical ganglion and in the coeliac-superior mesenteric ganglion complex of the rat. Histochemistry 1985; 82: 1-3.
8. Hill S. Distribution, properties, and functional characteristics of three classes of histamine receptors. Pharmacol Rev 1990; 42: 45-83.
9. Simons FER. Histamine and histamines. In Key AB, ed. Allergy and allergic diseases. Oxford: Blackwell Science; 1997. p. 421-38.
10. Kay AB. Concepts of allergy and hypersensitivity. In Key AB, ed. Allergy and allergic diseases. Oxford: Blackwell Science; 1997. p. 23-35.
11. Oehling A. Alergia, anafilaxia y atopía. Inmunidad. Inmunogenética. In Oehling A, ed. Alergología e inmunología Clínica. Madrid: McGraw-Hill-Interamericana de España; 1995. p. 3-12.
12. Sanz ML. Fundamentos de la respuesta alérgica. In Oehling A, ed. Alergología e inmunología clínica. Madrid: McGraw-Hill-Interamericana de España; 1995. p. 13-24.
13. Pardo FJ. Morfología de las reacciones alérgicas. In Oehling A, ed. Alergología e inmunología clínica. Madrid: McGraw-Hill-Interamericana de España; 1995. p. 125-38.
14. Jessell TM, Kelly DD. Pain and analgesia. In Kandel ER, Schwartz JH, Jessell TM, eds. Principles of Neural Science. Amsterdam: Elsevier Science Publishers BV; 1991. p. 385-99.
15. Gaillard JM, Nicholson AN, Pascoe PA. Neurotransmitter systems. In Kryger MH, Roth T, Dement WC, eds. Principles and practice of sleep medicine. London: WB Saunders; 1989. p. 202-12.
16. Monti JM. Efectos de la acetilcolina y de las aminas biógenas sobre el sueño y la vigilia. In Buela-Casal G, Navarro JF, eds. Avances en la investigación del sueño y sus trastornos. Madrid: Siglo Veintiuno; 1990. p. 79-103.
17. Monti JM. Involvement of histamine in the control of the waking state. Life Sci 1993; 53: 1331-8.
18. 1-receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene. Br J Pharmacol 1991; 104: 270-6.
19. 2 antagonists. Neuropharmacology 1985; 24: 245-50.
20. 11C]pyrilamine and positron emission tomography. J Neurochem 1992; 59: 128-36.
21. 3) visualized in the brain of human and non-human primates. Brain Res 1990; 526: 322-7.
22. 3) of histamine receptor. Nature 1983; 302: 832-7.
23. 3-receptors. Neuroscience 1987; 23: 149-57.
24. 3-receptors. Nature 1987; 327: 117-23.
25. Martindale W. Antihistamines. The Extra Pharmacopeia. London: Pharmaceutical Press; 1996. p. 427-56.
26. Vademécum Intemacional. Madrid: Medicom; 2001.
27. 1-receptor antagonists: clinical pharmacology and therapeutics. J Allergy Clin Immunol 1989; 84: 845-61.
28. Taglialatela M, Timmerman H, Annunziato L. Cardiotoxic potential and CNS effects of first-generation antihistamines. Trends Pharmacol Sci 2000; 21: 52-6.
29. Betts T, Markman D, Debenham S, Mortiboy D, McKevitt T. Effects of two antihistamine drugs on actual driving performance. Br Med J 1984; 288: 281-2.
30. 1-receptor antagonists: safety issues. Ann Allergy Asthma Immunol 1999; 83: 481-8.
31. Wyngaarden JB, Seevers MH. The toxic effects of antihistaminic drugs. JAMA 1951; 145: 277-82.
32. Greenberger P, Patterson R. Safety of therapy for allergic symptoms during pregnancy. Ann Intern Med 1978; 89: 234-7.
33. Aselton P, Jick H, Milunsky A, Hunter JR, Stergachis A. First-trimester drug use and congenital disorders. Obstet Gynecol 1985; 65: 451-5.
34. Zierler S, Purohit D. Prenatal antihistamine exposure and retrolental fibroplasia. Am J Epidemiol 1986; 123: 192-6.
35. 1-receptor antagonists. Eur J Clin Pharmacol 1985; 28: 523-9.
36. Horak F, Stubner UP. Comparative tolerability of second generation antihistamines. Drug Safety 1999; 20: 385-401.
37. De Roeck J, Cluydts R, Herman P. Effects of antihistamines on daytime alertness. J Allergy Clin Immunol 1990; 85: 179.
38. McQuade RD, Richlan K, Duffy RA, Chipkin RE, Barnett A. In vivo binding properties of non-sedating antihistamines to CNS histamine receptors. Drug Dev Res 1990; 20: 301-6.
39. Nicholson AN. Antihistamines and sedation. Lancet 1983; 2: 211-2.
40. Nicholson AN. New antihistamines free of sedative side-effects. TIPS 1987; 8: 247-9.
41. Pechadre JC, Vernay D, Trolese JF, Bloom M, Dupont P, Rihoux JP. Comparison of the central and peripheral effects of cetirizine and terfenadine. Eur J Clin Pharmacol 1988; 35: 255-9.
42. 1-antagonist terfenadine. Eur J Med Chem 1993; 28: 165-73.
43. 1-receptor antagonists for CNS and peripheral receptors? An in vitro study. Eur J Pharmacol 1993; 232: 199-205.
44. Walsh GM, Annunziato L, Frossard N, Knol K, Levander S, Nicolas JM, et al. New insights into the second generation antihistamines. Drugs 2001; 61: 207-36.
45. Gaillard AWK, Gruisen A, Jong R. The influence of antihistamines on human performance. Eur J Clin Pharmacol 1988; 35: 249-53.
46. Mattila MJ, Paakkari I. Variations among non-sedating antihistamines: are there real differences? Eur J Clin Pharmacol 1999; 55: 85-93.
47. Ryan JR, McMahon FG, Vargas R, Gotzkowsky S. Antimuscarinic activity of terfenadine (T), chlorpheniramine (C), atropine (A) and placebo (P) in normal volunteers. J Allergy Clin Immunol 1987; 79: 190.
48. Taylor RJ, Long WF, Nelson HS. The development of subsensitivity to chlorpheniramine. J Allergy Clin Immunol 1985; 76: 103-7.
49. Boobis AR, Burley D, Davies DM, Davies DS, Harrison PI, Orme MLE, et al. Chlorpheniramine (maleate). In Dollery C, ed. Therapeutic drugs. Madrid: Churchill Livingstone; 1991. p. 8-10.
50. 1-receptor occupancy. Clin Pharmacol Ther 1995; 58: 210-20.
51. Rumore MM. Clinical pharmacokinetics of chlorpheniramine. Drug Intell Clin Pharm 1984; 18: 701-7.
52. Gale AE, Harvey SG, Calthrop JG, Gibson JR. A comparison of acrivastine versus chlorpheniramine in the treatment of chronic idiopathic urticaria. J Int Med Res 1989; 17: 25-7B.
53. Bleehen SS, Thomas SE, Greaves MW, Newton J, Kennedy CTC, Hindley F, et al. Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multi-centre randomized double-blind study. Br J Dermatol 1987; 117: 81-8.
54. Howard JC, Kantner TR, Lilienfield LS, Princiotto JV, Krum RE, Crutcher JE, et al. Effectiveness of antihistamines in the symptomatic management of the common cold. JAMA 1979; 242: 2414-7.
55. Chua SS, Benrimoj SI, Gordon RD, Williams G. Cardiovascular effects of a chlorpheniramine/paracetamol combination in hypertensive patients who were sensitive to the pressor effect of pseudoephedrine. Br J Clin Pharmacol 1991; 31: 360-2.
56. Grant JA, Bernstein DI, Buckley CE, Chu T, Fox RW, Rocklin RE, et al. Double-blind comparison of terfenadine, chlorpheniramine, and placebo in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1988; 81: 574-9.
57. Batenhorst RL, Batenhorst AS, Graves DA, Foster TS, Kung M, Gural RP, et al. Pharmacological evaluation of loratadine (SCH 29851), chlorpheniramine and placebo. Eur J Clin Pharmacol 1986; 31: 247-50.
58. Simons FER, McMillan JL, Simons KJ. A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamineinduced wheals and flares during 24 hours in normal subjects. J Allergy Clin Immunol 1990; 86: 540-7.
59. 1-receptor blockade on the early and late response to cutaneous allergen challenge. J Pharmacol Exp Ther 1992; 262: 964-70.
60. Friedman BS, Santiago ML, Berkebile C, Metcalfe DD. Comparison of azelastine and chlorpheniramine in the treatment of mastocytosis. J Allergy Clin Immunol 1993; 92: 520-6.
61. Kaur S, Greaves M, Eftekhari N. Factitious urticaria (dermographism): treatment by cimetidine and chlorpheniramine in a randomized double-blind study. Br J Dermatol 1981; 104: 185-90.
62. Krause LB, Shuster S. A comparison of astemizole and chlorpheniramine in dermographic urticaria. Br J Dermatol 1985; 112: 447-53.
63. 1 blocker, chlorpheniramine. J Allergy Clin Immunol 1977; 59: 54-63.
64. 1-receptor antihistamines in the airways and skin of subjects with asthma. J Allergy Clin Immunol 1993; 91: 1005-14.
65. Wong L, Hendeles L, Weinberger M. Pharmacologic prophylaxis of allergic rhinitis: relative efficacy of hydroxyzone and chlorpheniramine. J Allergy Clin Immunol 1981; 67: 223-8.
66. Simons FER, Luciuk GH, Simons KJ. Pharmacokinetics and efficacy of chlorpheniramine in children. J Allergy Clin Immunol 1982; 69: 376-81.
67. Weiler JM, Donnelly A, Campbell BH, Connell JT, Diamond L, Hamilton LH, et al. Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis. J Allergy Clin Immunol 1988; 82: 801-11.
68. Helling DK, Milavetz G. Nonprescription drug screening: chlorpheniramine maleate. Am Pharmacol 1986; 26: 31-3.
69. Clarke CH, Nicholson AN. Performance studies with antihistamines. Br J Clin Pharmacol 1978; 6: 31-5.
70. Hindmarch I, Parrott C. A repeated dose comparison of the side effects of five antihistamines on objective assessments of psychomotor performance, central nervous system arousal and subjective appraisals of sleep and early morning behaviour. Drug Res 1978; 28: 483-6.
71. Kulshrestha VK, Gupta PP, Turner P, Wadsworth J. Some clinical pharmacological studies with terfenadine, a new antihistamine drug. Br J Clin Pharmacol 1978; 6: 25-9.
72. Chapman PH, Rawlins MD. A randomized single-blind study of astemizole and chlorpheniramine in normal volunteers. Br J Clin Pharmacol 1982; 13: 593.
73. Meador KJ, Loring DW, Thompson EE, Thompson WO. Differential cognitive effects of terfenadine and chlorpheniramine. J Allergy Clin Immunol 1989; 84: 322-5.
74. 1-receptor antagonists) terfenadine and chlorpheniramine in children. J Pediatr 1994; 124: 979-83.
75. Alford C, Bhatti JZ, Rombaut NEI, Curran S, Hindmarch I. A comparison of antihistamines using EEG and questionnaire-based assessments. Med Sci Res 1989; 17: 421-3.
76. Millet VM, Dreisbach M, Bryson YJ. Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine. Antimicrob Agents Chemother 1982; 21: 1-4.
77. Shanon A, Feldman W, Leikin L, Pong AH, Peterson R, Williams V. Comparison of CNS adverse effects between astemizole and chlorpheniramine in children: a randomized, double-blind study. Dev Pharmacol Ther 1993; 20: 239-46.
78. Millar K, Wilkinson RT. The effects upon vigilance and reaction speed of the addition of ephedrine hydrochloride to chlorpheniramine maleate. Eur J Clin Pharmacol 1981; 20: 351-7.
79. Simons KJ, Dilay DJ, Reggin JD, Fraser TG, Patrick JP, Simons FER. Cetrizine (C), hydroxizine (H), and diphenhydramine (D): studies of central nervous system effects using the P300 event-related potential. J Allergy Clin Immunol 1994; 93: 235.
80. Pritchard WS. Psychophysiology of P300. Psychol Bull 1981; 89: 506-40.
81. Parasuraman R, Beatty J. Brain events underlying detection and recognition of weak sensory signal. Science 1980; 210: 80-3.
82. 1-receptor antagonist chlorpheniramine decreases the ending phase of the mismatch negativity of the human auditory event-related potentials. Neurosci Lett 1996; 203: 77-80.
83. 1-receptor antagonist impairs selective auditory attention in the absence of subjective awareness of this impairment. J Clin Psychopharmacol 2001; 21: 599-602.
84. 1 antagonist, confirmed by the use of d-chlorpheniramine with monitoring electroencephalography. Method Find Exp Clin Pharmacol 1993; 15: 183-8.